Semaglutide can help eligible adults manage excess weight during perimenopause and after menopause, but it is not a treatment for menopause itself. Clinical trials show significant average weight loss with semaglutide in people with obesity or overweight and qualifying health conditions. However, research focused specifically on menopausal women remains limited.
One small study also found greater weight loss among postmenopausal women who were already taking menopausal hormone therapy (HRT). That finding is interesting, but it does not prove that adding HRT will make semaglutide more effective.
If you've noticed changes in your weight, waistline, or appetite during your 40s or 50s, you're not alone. Even familiar eating and exercise routines can feel less effective as your body changes.
The question is whether semaglutide can help, what the research actually shows, and what you should know before considering treatment.
Why Do Weight and Waist Size Change During Menopause?
Menopause involves major hormonal changes, but the relationship between menopause and weight gain is more complicated than a simple drop in estrogen.
Midlife weight gain and belly fat are not the same thing
Weight gain refers to an increase in overall body weight. Abdominal fat accumulation refers to a change in where the body stores fat.
These changes can occur together, but they are not identical.
During midlife, aging-related changes in metabolism, muscle mass, and activity levels can contribute to gradual weight gain. Declining estrogen levels during the menopause transition can also influence fat distribution, making abdominal fat more prominent.
This means someone might notice their waistline changing even when their weight has not increased dramatically.
A scale measures total body weight, while waist circumference provides additional information about abdominal fat distribution. Both can be useful when evaluating metabolic health.
According to theInternational Menopause Society's recommendations, midlife weight gain is driven largely by aging, while menopause-related hormonal changes contribute particularly to abdominal fat redistribution.
Other factors that influence weight during midlife
Hormones are only part of the picture.
Changes in sleep, daily activity, stress, muscle mass, and eating patterns can all affect weight management.
For example, night sweats and sleep disruptions may leave you feeling exhausted during the day. This can make regular exercise, meal planning, and consistent routines more difficult.
Loss of muscle mass with aging can also affect how the body uses energy.
These changes do not mean weight gain is inevitable. They do mean that an effective weight-management plan should consider your overall health rather than focusing exclusively on estrogen levels.
If weight changes are sudden, unexpected, or accompanied by new symptoms, a clinician can help evaluate other possible contributors.
How Does Semaglutide Work for Weight Management?
Semaglutide belongs to a class of medications called GLP-1 receptor agonists.
GLP-1 stands for glucagon-like peptide-1, a hormone involved in regulating appetite, digestion, and blood glucose.
Semaglutide activates GLP-1 receptors and affects several processes involved in eating behavior and metabolic regulation.
How semaglutide affects appetite and fullness
Semaglutide helps regulate appetite and increases feelings of fullness.
It also slows gastric emptying, particularly during the earlier stages of treatment, although this effect may change over time.
For some people, these effects make it easier to reduce food intake without feeling constantly hungry.
You may also hear people describe a reduction in food noise.
Food noise is an informal term for persistent thoughts about food, such as planning the next meal, thinking about snacks, or feeling preoccupied with eating.
Some patients report that these thoughts become less intrusive while using GLP-1 medications. However, the experience varies, and a reduction in food noise is not guaranteed.
Importantly, semaglutide is not a replacement for adequate nutrition, physical activity, or ongoing medical care.
Wegovy, Ozempic, and Zepbound: What's the difference?
These medications are often discussed together, but they are not interchangeable.
| Medication | Active ingredient | Main distinction |
| Wegovy | Semaglutide | FDA-approved for chronic weight management in eligible patients, among other indications. |
| Ozempic | Semaglutide | Primarily used for type 2 diabetes and certain related risk-reduction indications. |
| Zepbound | Tirzepatide | A different medication that acts on both GIP and GLP-1 receptors and has approved weight-management indications. |
Wegovy has both injectable and oral formulations in the United States as of 2026. The approved formulation, dose, and treatment instructions matter when comparing medications or interpreting research results.
The clinical trials discussed in this article primarily evaluated once-weekly injectable semaglutide 2.4 mg, so their results should not automatically be applied to every semaglutide formulation or dose.
For a more detailed comparison, read our guide toTirzepatide vs. Wegovy: What's the Difference?.
You can also exploretirzepatide for weight management to understand how that medication differs from semaglutide.
Does Semaglutide Work During Perimenopause or After Menopause?
The available evidence supports semaglutide as an effective weight-management medication for many eligible adults.
However, it is important to distinguish large clinical trials involving adults of different ages from smaller studies focused specifically on postmenopausal women.
What the STEP 1 clinical trial found
The STEP 1 trial, published in the New England Journal of Medicine in 2021, included 1,961 adults with obesity or overweight and at least one weight-related health condition. Participants did not have diabetes.
Researchers compared weekly semaglutide 2.4 mg injections with placebo over 68 weeks.
Both groups also received lifestyle support.
The results showed:
| Group | Average weight change at 68 weeks |
| Semaglutide | 14.9% weight loss |
| Placebo | 2.4% weight loss |
That represents an estimated difference of 12.4 percentage points between the groups.
These findings demonstrate clinically meaningful weight loss under the study conditions.
However, STEP 1 was not designed specifically to investigate menopause. Its results cannot tell us whether women in perimenopause respond differently from those who are postmenopausal.
Also, 14.9% is a study average, not a guaranteed outcome for an individual.
Read the STEP 1 clinical trial.
What do we know about postmenopausal women?
A 2024 study conducted by researchers associated with Mayo Clinic examined weight-loss responses among 106 postmenopausal women receiving semaglutide.
Some of these women were using menopausal hormone therapy, while others were not.
Both groups experienced weight loss during semaglutide treatment.
The study provides useful early information, but it was retrospective and observational rather than randomized.
That means researchers looked at existing patient data instead of randomly assigning participants to hormone therapy.
The findings suggest semaglutide can be associated with weight loss in postmenopausal patients, but the study does not establish whether menopause status changes its effectiveness compared with other adults.
For someone in perimenopause, there is even less direct research addressing that specific question.
The practical takeaway: Menopause status alone does not determine whether semaglutide is appropriate. Eligibility depends on weight-related criteria, medical history, treatment goals, and clinical assessment.
Can You Take Semaglutide and Hormone Therapy Together?
This is an increasingly common question, particularly among women considering treatment for both menopause symptoms and excess weight.
The first thing to understand is that these treatments serve different purposes.
Semaglutide and HRT address different health concerns
Menopausal hormone therapy, commonly called HRT, may be considered for symptoms such as hot flashes, night sweats, and certain genitourinary symptoms, depending on an individual's medical history.
Semaglutide is used for specific metabolic and weight-management indications.
HRT is not routinely prescribed simply to promote weight loss.
Likewise, semaglutide should not be expected to relieve hot flashes, night sweats, or other menopause-specific symptoms.
For some patients, separate treatment plans may be appropriate for different concerns. Any combination should be reviewed by a qualified clinician, including the formulations being used and possible medication interactions.
What the 2024 Mayo Clinic study found
In the 2024 retrospective study, researchers compared postmenopausal women receiving semaglutide who were using hormone therapy with those who were not.
The groups included:
- 16 women using hormone therapy.
- 90 women not using hormone therapy.
At 12 months, reported average weight loss was:
| Group | Average weight loss |
| Semaglutide + existing hormone therapy | 16% |
| Semaglutide without hormone therapy | 12% |
The difference was 4 percentage points.
That is an association worth investigating further.
However, the study was small, and hormone therapy use was not randomly assigned.
Participants may have differed in ways that influenced treatment outcomes, including their general health, clinical care, or other characteristics.
Therefore, we cannot conclude that starting HRT would produce an additional four percentage points of weight loss.
We also cannot conclude that HRT makes semaglutide more effective for every postmenopausal woman.
The study's authors called for further research.
Read the 2024 study: Weight Loss Response to Semaglutide in Postmenopausal Women.
Bottom line: If you're already taking HRT, discuss all medications with your prescriber. But the available evidence does not support starting HRT solely to increase semaglutide-related weight loss.
Who Might Qualify for Semaglutide During Menopause?
For adults seeking prescription weight-management treatment, commonly used eligibility criteria include:
- A body mass index (BMI) of 30 or higher, indicating obesity.
- A BMI of 27 or higher, together with at least one weight-related health condition.
Examples of weight-related conditions may include hypertension, dyslipidemia, or obstructive sleep apnea.
However, BMI is not the entire assessment.
A clinician should also consider medical history, medications, pregnancy plans, weight-related complications, previous treatments, and the benefits and risks of available options.
Someone who has gained a few pounds during perimenopause does not automatically qualify for semaglutide.
Likewise, reaching menopause does not automatically make weight-management medication necessary.
For readers unfamiliar with peptide-based medications, ourbeginner's guide to peptide therapy explains important differences between treatment categories.
Semaglutide Side Effects and Safety Considerations
Like any prescription medication, semaglutide has potential side effects and contraindications.
Common side effects
The most commonly reported effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion.
Some people also experience fatigue, bloating, or reduced tolerance for certain meals.
Gastrointestinal side effects may be more noticeable during treatment initiation or dose increases.
A healthcare professional can discuss how treatment is introduced and monitored, including how to respond to side effects.
Important medical warnings
Semaglutide products carry important safety warnings.
Wegovy has a boxed warning concerning thyroid C-cell tumors observed in rodents. It is not known whether semaglutide causes these tumors in humans.
Wegovy is contraindicated for people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
It should also not be used by people with a prior serious hypersensitivity reaction to semaglutide or relevant product ingredients.
Other safety considerations include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney problems, and interactions with other treatments.
Severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or symptoms of a serious allergic reaction require prompt medical attention.
A clinician should also review relevant digestive conditions, diabetes medications, planned procedures involving anesthesia, and other medical circumstances.
What if you're still able to become pregnant?
This is especially important during perimenopause.
Menstrual cycles may become irregular, but pregnancy can still occur before menopause is established.
For weight management, Wegovy should be discontinued when pregnancy is recognized. Its prescribing information also recommends stopping at least two months before a planned pregnancy.
Discuss pregnancy intentions and contraception with your clinician before beginning treatment.
You can review theofficial Wegovy prescribing information for detailed safety information.
How Can You Protect Muscle, Bone Health, and Long-Term Results?
Successful weight management during menopause is about more than seeing a lower number on the scale.
Changes in muscle mass, bone health, physical function, and metabolic risk are especially important during midlife.
Prioritize adequate nutrition
Semaglutide can significantly reduce appetite.
While that may support a calorie deficit, eating substantially less can make it harder to obtain adequate protein, vitamins, minerals, and other nutrients.
A balanced eating plan should account for your nutritional needs, current health conditions, and level of physical activity.
Protein intake deserves particular attention because maintaining muscle becomes increasingly important with age.
Rather than relying on a universal protein target, ask a registered dietitian or healthcare professional what is appropriate for your circumstances.
Include resistance training
Strength training helps support muscle function and physical independence.
Activities using resistance bands, weights, machines, or body weight can be adapted to different fitness levels.
Combining regular movement with appropriate nutrition can help protect strength while weight changes.
Walking and other aerobic activities also provide valuable cardiovascular benefits.
Discuss your bone health
Menopause is associated with changes in bone metabolism.
Depending on age, fracture history, nutritional status, and other risk factors, a clinician may recommend evaluating bone health.
Semaglutide should not be described as inevitably causing osteoporosis, but substantial weight loss should be managed with attention to overall nutrition and musculoskeletal health.
Plan for long-term weight maintenance
Weight management often requires ongoing support.
The STEP 1 extension study found that, one year after participants stopped semaglutide and the structured lifestyle intervention, they had regained approximately two-thirds of their previous weight loss on average.
This does not mean everyone will regain the same amount, but it illustrates why long-term planning matters.
Before starting medication, discuss:
- How treatment success will be measured.
- What happens if side effects become difficult to manage.
- Whether the medication is financially sustainable.
- How nutrition and activity will be supported.
- What the follow-up and maintenance plan will look like.
Do not assume that independently reducing doses, using unprescribed microdoses, or replacing medication with supplements will provide equivalent results.
Read the STEP 1 weight-regain study.
Is Semaglutide the Right Choice for Menopause Weight Gain?
There is no single answer for everyone.
For someone with obesity or overweight and associated medical concerns, semaglutide may be an appropriate option after clinical evaluation.
For someone experiencing primarily hot flashes, disrupted sleep, or a modest change in abdominal fat without meeting treatment criteria, a different approach may be more appropriate.
The best starting point is identifying what has changed and why.
This might involve reviewing weight history, waist circumference, sleep, medications, symptoms, lifestyle patterns, and relevant medical conditions.
For some people, the next step will be a structured nutrition and exercise plan. For others, it may involve discussing prescription weight-management treatment, menopause symptom management, or both as separate clinical decisions.
If you're researching medication options, our guide tohow to get a peptide prescription explains why appropriate medical evaluation, legitimate prescribing, and ongoing monitoring matter.
Frequently Asked Questions
Can I take semaglutide during perimenopause, or do I have to wait until after menopause?
You do not necessarily need to wait until after menopause. If you meet the appropriate medical criteria, a clinician may consider semaglutide during perimenopause. Your overall health, pregnancy plans, medications, and treatment goals are more important than menopause status alone.
Does semaglutide target menopause belly fat specifically?
Semaglutide supports overall weight reduction and can reduce body fat, but it does not selectively target menopause-related abdominal fat. Changes in waist circumference may occur as part of broader weight loss. Menopause-related fat distribution is influenced by several factors.
Can I take Wegovy if I'm already on HRT?
Some patients may use semaglutide and hormone therapy under medical supervision. However, suitability depends on your health history and the specific medications and formulations involved. The available evidence does not establish that starting HRT increases semaglutide effectiveness.
Does semaglutide help with hot flashes or night sweats?
Semaglutide is not an established treatment for hot flashes, night sweats, or other menopause-specific symptoms. These concerns should be evaluated separately, and evidence-based menopause treatments may be appropriate.
What happens if I stop taking semaglutide?
Weight regain can occur after stopping treatment. In the STEP 1 extension study, participants regained approximately two-thirds of their previous weight loss on average during the following year. Discuss a maintenance plan with your healthcare professional before making treatment changes.
What should I bring to a weight-management consultation?
Bring your medication and supplement list, relevant medical history, previous weight-management treatments, recent laboratory results if available, and information about menopause symptoms or hormone therapy.
It can also help to discuss sleep, eating patterns, physical activity, pregnancy plans, and your expectations for treatment.
Final Thoughts: Semaglutide and Menopause
Semaglutide can be an effective weight-management medication for eligible adults, including some women navigating perimenopause or postmenopause.
The evidence supports meaningful average weight loss, but treatment responses vary.
Research examining semaglutide specifically during menopause is still developing. The 2024 hormone therapy study offers an interesting early finding, but it does not prove that adding HRT improves weight-loss outcomes.
Most importantly, semaglutide treats certain weight-related health concerns, not menopause itself.
If your weight, waist size, or appetite has changed during midlife, a medical consultation can help clarify what may be contributing and which options are appropriate.
Explore Your Options With Drip Lounge
Drip Lounge provides access toonline wellness consultations, where you can discuss your health goals and ask about relevant evaluation options.
A consultation can help determine whether further assessment, lifestyle support, or a medically appropriate treatment pathway is worth considering.
CTA: Explore Online Consultations
Consultation availability and treatment options are subject to clinical eligibility. A consultation does not guarantee a prescription or a particular weight-loss result.
Medical References
- Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine.
- Weight Loss Response to Semaglutide in Postmenopausal Women With and Without Hormone Therapy Use (2024). Menopause.
- Wilding JPH, et al. (2022). Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes, Obesity and Metabolism.
- International Menopause Society Recommendations and Key Messages on Women's Midlife Health and Menopause.
- U.S. National Library of Medicine. Wegovy Prescribing Information.